Skip to content
2000
Volume 32, Issue 32
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Aims

The purpose of this study was to investigate the prognostic significance of cholesterol uptake genes in predicting the survival of breast cancer patients.

Background

Cholesterol plays a crucial role in the homeostasis of tumor cells. It is known that cholesterol levels can influence important parameters of the disease, such as sensitivity to therapy, progression, and metastasis of cancer. Previous studies suggest that breast cancer subtypes exhibit differences in metabolism.

Objective

The objectives of this study were to determine whether cholesterol uptake genes have prognostic significance for overall survival in breast cancer patients, evaluate if this prognostic significance varies between breast cancer subtypes, and identify differences in the expression of cholesterol uptake genes among these subtypes.

Methods

Data from mRNA sequencing of tumors from the Cancer Genome Atlas (TCGA) portal were analyzed. Tumors were classified into molecular subtypes, and the prognostic significance of cholesterol uptake gene expression levels was evaluated for each subtype. DESeq2 and Fisher's test were used to assess differences in gene expression.

Results

High expression levels of genes involved in cholesterol synthesis were associated with poor prognosis for the Basal-like and Luminal A breast cancer subtypes. The prognostic significance of low-density lipoprotein receptor (LDLR), LDLR adapter protein 1 (LDLRAP1), and proprotein convertase subtilisin/kexin type 9 (PCSK9), which are responsible for exogenous cholesterol uptake, varied across subtypes. Specifically, low expression of LDLR was associated with a favorable prognosis for the luminal A (OR = 2.17; FDR = 0.0048) and luminal B (OR = 2.21; FDR = 0.015) subtypes but indicated poor prognosis in the basal-like subtype (OR = 0.48; FDR = 0.05). No genes were significant for prognosis prediction in the HER2-positive subtype. The HER2+ subtype exhibited higher expression of cholesterol uptake genes compared to the basal-like subtype based on the analysis of tumor mRNA sequencing (OR = 6.45, -value = 3.07E-05). This finding was also confirmed through the study of publicly available single-cell sequencing data (OR = 40.3, -value = 2.19e-07), which may contribute to the differences in their prognostic significance.

Conclusion

The prognostic significance of cholesterol uptake gene expression varies among breast cancer subtypes. Precise fitting of biomarkers into breast cancer subtypes may aid in more accurate patient stratification and improve treatment approaches.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673291217241219055416
2025-01-20
2025-10-25

  • From This Site

    /content/journals/cmc/10.2174/0109298673291217241219055416
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TranK.B. LangJ.J. ComptonK. XuR. AchesonA.R. HenriksonH.J. KocarnikJ.M. PenberthyL. AaliA. AbbasQ. AbbasiB. KangevariA.M. KangevariA.Z. AbbastabarH. AbdelmassehM. Abd-ElsalamS. AbdelwahabA.A. AbdoliG. AbdulkadirH.A. AbediA. AbegazK.H. AbidiH. AboagyeR.G. AbolhassaniH. AbsalanA. AbtewY.D. AliA.H. GharbiehA.E. AchappaB. AcunaJ.M. AddisonD. AddoI.Y. AdegboyeO.A. AdesinaM.A. AdnanM. AdnaniQ.E.S. AdvaniS.M. AfrinS. AfzalM.S. AggarwalM. AhinkorahB.O. AhmadA.R. AhmadR. AhmadS. AhmadS. AhmadiS. AhmedH. AhmedL.A. AhmedM.B. RashidA.T. AimanW. AjamiM. AkaluG.T. KhiaviA.M. AkliluA. AkondeM. AkunnaC.J. Al HamadH. AlahdabF. AlaneziF.M. AlanziT.M. AlessyS.A. AlgammalA.M. Al-HanawiM.K. AlhassanR.K. AliB.A. AliL. AliS.S. AlimohamadiY. AlipourV. AljunidS.M. AlkhayyatM. Al-MaweriS.A.A. AlmustanyirS. AlonsoN. AlqalyoobiS. Al-RaddadiR.M. Al-RifaiR.H.H. Al-SabahS.K. Al-TammemiA.B. AltawalahH. GuzmanA.N. AmareF. AmeyawE.K. DehkordiA.J.J. IranaqA.M.H. AmuH. AmusaG.A. AncuceanuR. AndersonJ.A. AnimutY.A. AnoushiravaniA. AnoushirvaniA.A. MoghaddamA.A. AnshaM.G. AntonyB. AntwiM.H. AnwarS.L. AnwerR. AnyasodorA.E. ArablooJ. ZozaniA.M. AremuO. ArgawA.M. AriffinH. AripovT. ArshadM. ArtamanA. ArulappanJ. ArulebaR.T. AryannejadA. AsaadM. AsemahagnM.A. AsemiZ. JafarabadiA.M. AshrafT. AssadiR. AtharM. AthariS.S. AtoutM.M.W. AttiaS. AujayebA. AusloosM. BurgosA.L. AwedewA.F. AwokeM.A. AwokeT. QuintanillaA.B.P. AyanaT.M. AyenS.S. AzadiD. AzadnajafabadS. AghdashA.S. AzanawM.M. KhyavyA.M. JafariA.A. AziziH. AzzamA.Y.Y. BabajaniA. BadarM. BadiyeA.D. BaghcheghiN. BagheriN. BagheriehS. BahadoryS. BaigA.A. BakerJ.L. BakhtiariA. BakshiR.K. BanachM. BanerjeeI. BardhanM. AdesiB.F. BarraF. BarrowA. BashirN.Z. BashiriA. BasuS. BatihaA-M.M. BegumA. BekeleA.B. BelayA.S. BeleteM.A. BelgaumiU.I. BellA.W. BeloL. BenzianH. BerhieA.Y. BermudezA.N.C. BernabeE. BhagavathulaA.S. BhalaN. BhandariB.B. BhardwajN. BhardwajP. BhattacharyyaK. BhojarajaV.S. BhuyanS.S. BibiS. BilchutA.H. BintoroB.S. BiondiA. BiregaM.G.B. BirhanH.E. BjørgeT. BlyussO. BodichaB.B.A. BollaS.R. BoloorA. BosettiC. BraithwaiteD. BrauerM. BrennerH. BrikoA.N. BrikoN.I. BuchananC.M. BulamuN.B. TeixeiraB.M.T. ButtM.H. ButtN.S. ButtZ.A. SantosC.F.L. CámeraL.A. CaoC. CaoY. CarrerasG. CarvalhoM. CembranelF. CerinE. ChakrabortyP.A. CharalampousP. ChattuV.K. Chimed-OchirO. CaceresC.J.L. ChoD.Y. ChoW.C.S. ChristopherD.J. ChuD-T. ChukwuI.S. CohenA.J. CondeJ. CortésS. CostaV.M. MartinsC.N. CulbrethG.T. DadrasO. DagnawF.T. DahlawiS.M.A. DaiX. DandonaL. DandonaR. DaneshpajouhnejadP. DanielewiczA. DaoA.T.M. SoltaniD.C.R. DarweshA.M. DasS. DavitoiuD.V. EsmaeiliD.E. HozD.L.F.P. DebelaS.A. DehghanA. DemisseB. DemisseF.W. GutiérrezD.E. DerakhshaniA. Derbew MollaM. DerejeD. DeribeK.S. DesaiR. DesalegnM.D. DessalegnF.N. DessalegniS.A.A. DessieG. DestaA.A. DewanS.M.R. DharmaratneS.D. DhimalM. DianatinasabM. DiaoN. DiazD. DigesaL.E. DixitS.G. DoaeiS. DoanL.P. DokuP.N. DongarwarD. dos SantosW.M. DriscollT.R. DsouzaH.L. DurojaiyeO.C. EdalatiS. EghbalianF. Ehsani-ChimehE. EiniE. EkholuenetaleM. EkundayoT.C. EkwuemeD.U. El TantawiM. ElbahnasawyM.A. ElbaraziI. ElghazalyH. ElhadiM. El-HuneidiW. EmamianM.H. Engelbert BainL. EnyewD.B. ErkhembayarR. EshetuT. EshratiB. EskandariehS. Espinosa-MonteroJ. EtaeeF. EtemadimaneshA. EyayuT. EzeonwumeluI.J. EzzikouriS. FagbamigbeA.F. FahimiS. FakhradiyevI.R. FaraonE.J.A. FaresJ. FarmanyA. FarooqueU. FarrokhpourH. FasanmiA.O. FatehizadehA. FatimaW. FattahiH. FekaduG. FelekeB.E. FerrariA.A. FerreroS. Ferro DesideriL. FilipI. FischerF. ForoumadiR. ForoutanM. FukumotoT. GaalP.A. GadM.M. GadanyaM.A. GaipovA. GalehdarN. GallusS. GargT. Gaspar FonsecaM. GebremariamY.H. GebremeskelT.G. GebremichaelM.A. GedaY.F. GelaY.Y. GemedaB.N.B. GetachewM. GetachewM.E. GhaffariK. GhafourifardM. GhamariS-H. Ghasemi NourM. GhassemiF. GhimireA. GhithN. GholamalizadehM. Gholizadeh NavashenaqJ. GhozyS. GilaniS.A. GillP.S. GinindzaT.G. GizawA.T.T. GlasbeyJ.C. GodosJ. GoelA. GolechhaM. GoleijP. GolinelliD. GolitalebM. GoriniG. GoulartB.N.G. GrossoG. GuadieH.A. GubariM.I.M. GudayuT.W. GuerraM.R. GunawardaneD.A. GuptaB. GuptaS. GuptaV.B. GuptaV.K. GuraraM.K. GutaA. HabibzadehP. Haddadi AvvalA. Hafezi-NejadN. Hajj AliA. Haj-MirzaianA. HalboubE.S. HalimiA. HalwaniR. HamadehR.R. HameedS. HamidiS. HanifA. HaririS. HarliantoN.I. HaroJ.M. HartonoR.K. HasaballahA.I. HasanS.M.M. HasaniH. HashemiS.M. HassanA.M. HassanipourS. HayatK. HeidariG. HeidariM. HeidarymeybodiZ. Herrera-SernaB.Y. HerteliuC. HezamK. HiraikeY. HlongwaM.M. HollaR. HolmM. HoritaN. HoseiniM. HossainM.M. HossainM.B.H. HosseiniM-S. HosseinzadehA. HosseinzadehM. HostiucM. HostiucS. HousehM. HuangJ. HugoF.N. HumayunA. HussainS. HusseinN.R. HwangB-F. IbitoyeS.E. IftikharP.M. IkutaK.S. IlesanmiO.S. IlicI.M. IlicM.D. ImmuranaM. InnosK. IranpourP. IrhamL.M. IslamM.S. IslamR.M. IslamiF. IsmailN.E. IsolaG. IwagamiM. JL.M. JaiswalA. JakovljevicM. JaliliM. JalilianS. JamshidiE. JangS-I. JaniC.T. JavaheriT. JayarajahU.U. JayaramS. JazayeriS.B. JebaiR. JemalB. JeongW. JhaR.P. JindalH.A. John-AkinolaY.O. JonasJ.B. JooT. JosephN. JoukarF. JozwiakJ.J. JürissonM. KabirA. KacimiS.E.O. KadashettiV. KaheF. KakodkarP.V. KalankeshL.R. KalankeshL.R. KalhorR. KamalV.K. KamangarF. KamathA. KanchanT. KandaswamyE. KandelH. KangH.J. KannoG.G. KapoorN. KarS.S. KaranthS.D. KarayeI.M. KarchA. KarimiA. KassaB.G. KatotoP.D.M.C. KauppilaJ.H. KaurH. KebedeA.G. Keikavoosi-AraniL. KejelaG.G. Kemp BohanP.M. KeramatiM. KeykhaeiM. KhajuriaH. KhanA. KhanA.A.K. KhanE.A. KhanG. KhanM.N. KhanM.A.B. KhanaliJ. KhatabK. KhatatbehM.M. KhatibM.N. KhayamzadehM. Khayat KashaniH.R. Khazeei TabariM.A. KhezeliM. KhodadostM. KimM.S. KimY.J. KisaA. KisaS. KlugarM. KlugarováJ. KolahiA-A. KolkhirP. KompaniF. KoulP.A. Koulmane LaxminarayanaS.L. KoyanagiA. KrishanK. KrishnamoorthyY. Kucuk BicerB. KugbeyN. KulimbetM. KumarA. KumarG.A. KumarN. KurmiO.P. KuttikkattuA. La VecchiaC. LahiriA. LalD.K. LámJ. LanQ. LandiresI. LarijaniB. LasradoS. LauJ. LauriolaP. LeddaC. LeeS. LeeS.W.H. LeeW-C. LeeY.Y. LeeY.H. LegesseS.M. LeighJ. LeongE. LiM-C. LimS.S. LiuG. LiuJ. LoC-H. LohiyaA. LopukhovP.D. LorenzoviciL. LotfiM. LoureiroJ.A. LuneviciusR. MadadizadehF. MafiA.R. MagdeldinS. MahjoubS. MahmoodpoorA. MahmoudiM. MahmoudimaneshM. MahumudR.A. MajeedA. MajidpoorJ. MakkiA. MakrisK.C. Malakan RadE. MalekpourM-R. MalekzadehR. MalikA.A. MallhiT.H. MallyaS.D. MamunM.A. MandaA.L. Mansour-GhanaeiF. MansouriB. MansourniaM.A. MantovaniL.G. MartiniS. MartorellM. MasoudiS. MasoumiS.Z. MateiC.N. MathewsE. MathurM.R. MathurV. McKeeM. MeenaJ.K. MehmoodK. Mehrabi NasabE. MehrotraR. MeleseA. MendozaW. MenezesR.G. MengeshaS.I.D. MensahL.G. MentisA-F.A. Mera-MamiánA.Y.M. MeretojaT.J. MeridM.W. MershaA.G. MeseluB.T. MeshkatM. MestrovicT. Miao JonassonJ. MiazgowskiT. MichalekI.M. MijenaG.F.W. MillerT.R. MirS.A. MirinezhadS.K. MirmoeeniS. Mirza-Aghazadeh-AttariM. MirzaeiH. MirzaeiH.R. MisganawA.S. MisraS. MohammadK.A. MohammadiE. MohammadiM. Mohammadian-HafshejaniA. MohammadpourhodkiR. MohammedA. MohammedS. MohanS. MohseniM. MokaN. MokdadA.H. MolassiotisA. MolokhiaM. MomenzadehK. MomtazmaneshS. MonastaL. MonsU. MontasirA.A. MontazeriF. MonteroA. MoosaviM.A. MoradiA. MoradiY. Moradi SarabiM. MoragaP. MorawskaL. MorrisonS.D. MorzeJ. MosapourA. MostafaviE. MousaviS.M. Mousavi IsfahaniH. Mousavi KhaneghahA. Mpundu-KaambwaC. MubarikS. MulitaF. MunblitD. MunroS.B. Murillo-ZamoraE. MusaJ. NabhanA.F. NagarajanA.J. NagarajuS.P. NagelG. NaghipourM. NaimzadaM.D. NairT.S. NaqviA.A. Narasimha SwamyS. NarayanaA.I. NassereldineH. NattoZ.S. NayakB.P. NdejjoR. NduagubaS.O. NegashW.W. NejadghaderiS.A. NejatiK. Neupane KandelS. NguyenH.V.N. NiaziR.K. NoorN.M. NooriM. NorooziN. NouraeiH. NowrooziA. Nuñez-SamudioV. NzoputamC.I. NzoputamO.J. OanceaB. OdukoyaO.O. OghenetegaO.B. OgunsakinR.E. OguntadeA.S. OhI-H. Okati-AliabadH. OkekunleA.P. OlagunjuA.T. OlagunjuT.O. OlakundeB.O. OlufadewaI.I. OmerE. OmonisiA.E.E. OngS. OnwujekweO.E. OrruH. OtstavnovS.S. OulhajA. OumerB. OwopetuO.F. OyinloyeB.E. P AM. Padron-MonederoA. PadubidriJ.R. PakbinB. PakshirK. PakzadR. PaliczT. PanaA. PandeyA. PandeyA. PantS. PardhanS. ParkE-C. ParkE-K. ParkS. PatelJ. PatiS. PaudelR. PaudelU. PaunM. Pazoki ToroudiH. PengM. PereiraJ. PereiraR.B. PernaS. PerumalsamyN. PestellR.G. PezzaniR. PiccinelliC. PillayJ.D. PirachaZ.Z. PischonT. PostmaM.J. Pourabhari LangroudiA. PourshamsA. PourtaheriN. PrashantA. QadirM.M.F. Quazi SyedZ. RabieeM. RabieeN. RadfarA. RadhakrishnanR.A. RadhakrishnanV. RaeisiM. RafieeA. RafieiA. RaheemN. RahimF. RahmanM.O. RahmanM. RahmanM.A. RahmaniA.M. RahmaniS. RahmanianV. RajaiN. RajeshA. RamP. RamezanzadehK. RanaJ. RanabhatK. RanasingheP. RaoC.R. RaoS.J. RashediS. RashidiA. RashidiM. RashidiM-M. RatanZ.A. RawafD.L. RawafS. RawalL. RawassizadehR. RazeghiniaM.S. RehmanA.U. RehmanI. ReitsmaM.B. RenzahoA.M.N. RezaeiM. RezaeiN. RezaeiN. RezaeiN. RezaeiS. RezaeianM. RezapourA. RiadA. RikhtegarR. Rios-BlancasM. RobertsT.J. RohloffP. Romero-RodríguezE. RoshandelG. RwegereraG.M. SM. Saber-AyadM.M. Saberzadeh-ArdestaniB. SabourS. SaddikB. SadeghiE. SaebM.R. SaeedU. SafaeiM. SafaryA. SahebazzamaniM. SahebkarA. SahooH. SajidM.R. SalariH. SalehiS. SalemM.R. SalimzadehH. SamodraY.L. SamyA.M. SanabriaJ. SankararamanS. SanmarchiF. Santric-MilicevicM.M. SaqibM.A.N. SarveazadA. SarviF. SathianB. SatpathyM. SayeghN. SchneiderI.J.C. SchwarzingerM. ŠekerijaM. SenthilkumaranS. SepanlouS.G. SeylaniA. SeyoumK. ShaF. ShafaatO. ShahP.A. ShahabiS. ShahidI. ShahrbafM.A. ShahsavariH.R. ShaikhM.A. ShakaM.F. ShakerE. ShannawazM. SharewM.M.S. SharifiA. Sharifi-RadJ. SharmaP. ShashamoB.B. SheikhA. SheikhM. SheikhbahaeiS. SheikhiR.A. SheikhyA. ShepherdP.R. ShettyA. ShettyJ.K. ShettyR.S. ShibuyaK. ShirkoohiR. Shirzad-AskiH. ShivakumarK.M. ShivalliS. ShivarovV. ShobeiriP. Shokri VarniabZ. ShorofiS.A. ShresthaS. SibhatM.M. Siddappa MalleshappaS.K. SidemoN.B. SilvaD.A.S. SilvaL.M.L.R. Silva JulianG. SilvestrisN. SimegnW. SinghA.D. SinghA. SinghG. SinghH. SinghJ.A. SinghJ.K. SinghP. SinghS. SinhaD.N. SinkeA.H. SirajM.S. SitasF. SiwalS.S. SkryabinV.Y. SkryabinaA.A. SoceaB. SoebergM.J. Sofi-MahmudiA. SolomonY. Soltani-ZangbarM.S. SongS. SongY. SorensenR.J.D. SoshnikovS. SotoudehH. SoweA. SufiyanM.B. SukR. SulemanM. Suliankatchi AbdulkaderR. SultanaS. SurD. SzócskaM. TabaeianS.P. Tabarés-SeisdedosR. TabatabaeiS.M. TabuchiT. TadbiriH. TaheriE. TaheriM. Taheri SoodejaniM. TakahashiK. TalaatI.M. TampaM. TanK-K. TatN.Y. TatV.Y. TavakoliA. TavakoliA. Tehrani-BanihashemiA. TekalegnY. TesfayF.H. ThaparR. ThavamaniA. Thoguluva ChandrasekarV. ThomasN. ThomasN.K. TicoaluJ.H.V. TiyuriA. TollosaD.N. Topor-MadryR. TouvierM. Tovani-PaloneM.R. TrainiE. TranM.T.N. TripathyJ.P. UkkeG.G. UllahI. UllahS. UllahS. UnnikrishnanB. VacanteM. VaeziM. Valadan TahbazS. ValdezP.R. VardavasC. VarthyaS.B. VaziriS. VelazquezD.Z. VerouxM. VilleneuveP.J. ViolanteF.S. VladimirovS.K. VlassovV. VoB. VuL.G. WadoodA.W. WaheedY. WaldeM.T. WamaiR.G. WangC. WangF. WangN. WangY. WardP. WarisA. WestermanR. WickramasingheN.D. WoldemariamM. WolduB. XiaoH. XuS. XuX. YadavL. JabbariY.S.H. YangL. YazdanpanahF. YeshawY. YismawY. YonemotoN. YounisM.Z. YousefiZ. YousefianF. YuC. YuY. YunusaI. ZahirM. ZakiN. ZamanB.A. ZangiabadianM. ZareF. ZareI. ZareshahrabadiZ. ZarrintanA. ZastrozhinM.S. ZeineddineM.A. ZhangD. ZhangJ. ZhangY. ZhangZ-J. ZhouL. ZodpeyS. ZoladlM. VosT. HayS.I. ForceL.M. MurrayC.J.L. The global burden of cancer attributable to risk factors, 2010–19: A systematic analysis for the global burden of disease study 2019.Lancet20224001035256359110.1016/S0140‑6736(22)01438‑635988567
     [Google Scholar]
  2. AzamjahN. ZadehS.Y. ZayeriF. Global trend of breast cancer mortality rate: A 25-year study. Asian Pac. J. Cancer Prev.20192072015202010.31557/APJCP.2019.20.7.201531350959
     [Google Scholar]
  3. KocarnikJ.M. ComptonK. DeanF.E. FuW. GawB.L. HarveyJ.D. HenriksonH.J. LuD. PenniniA. XuR. AbabnehE. KangevariA.M. AbbastabarH. Abd-ElsalamS.M. AbdoliA. AbediA. AbidiH. AbolhassaniH. AdedejiI.A. AdnaniQ.E.S. AdvaniS.M. AfzalM.S. AghaaliM. AhinkorahB.O. AhmadS. AhmadT. AhmadiA. AhmadiS. RashidA.T. SalihA.Y. AkaluG.T. AkliluA. AkramT. AkunnaC.J. Al HamadH. AlahdabF. Al-AlyZ. AliS. AlimohamadiY. AlipourV. AljunidS.M. AlkhayyatM. Almasi-HashianiA. AlmasriN.A. Al-MaweriS.A.A. AlmustanyirS. AlonsoN. Alvis-GuzmanN. AmuH. AnbesuE.W. AncuceanuR. AnsariF. Ansari-MoghaddamA. AntwiM.H. AnvariD. AnyasodorA.E. AqeelM. ArablooJ. Arab-ZozaniM. AremuO. AriffinH. AripovT. ArshadM. ArtamanA. ArulappanJ. AsemiZ. Asghari JafarabadiM. AshrafT. AtorkeyP. AujayebA. AusloosM. AwedewA.F. Ayala QuintanillaB.P. AyenewT. AzabM.A. AzadnajafabadS. Azari JafariA. AzarianG. AzzamA.Y. BadiyeA.D. BahadoryS. BaigA.A. BakerJ.L. BalakrishnanS. BanachM. BärnighausenT.W. Barone-AdesiF. BarraF. BarrowA. BehzadifarM. BelgaumiU.I. BezabheW.M.M. BezabihY.M. BhagatD.S. BhagavathulaA.S. BhardwajN. BhardwajP. BhaskarS. BhattacharyyaK. BhojarajaV.S. BibiS. BijaniA. BiondiA. BisignanoC. BjørgeT. BleyerA. BlyussO. BolarinwaO.A. BollaS.R. BraithwaiteD. BrarA. BrennerH. Bustamante-TeixeiraM.T. ButtN.S. ButtZ.A. Caetano dos SantosF.L. CaoY. CarrerasG. Catalá-LópezF. CembranelF. CerinE. CernigliaroA. ChakinalaR.C. ChattuS.K. ChattuV.K. ChaturvediP. Chimed-OchirO. ChoD.Y. ChristopherD.J. ChuD.T. ChungM.T. CondeJ. CortésS. CortesiP.A. CostaV.M. CunhaA.R. DadrasO. DagnewA.B. DahlawiS.M.A. DaiX. DandonaL. DandonaR. DarweshA.M. das NevesJ. De la HozF.P. DemisA.B. Denova-GutiérrezE. DhamnetiyaD. DhimalM.L. DhimalM. DianatinasabM. DiazD. DjalaliniaS. DoH.P. DoaeiS. DorostkarF. dos Santos FigueiredoF.W. DriscollT.R. EbrahimiH. EftekharzadehS. El TantawiM. El-AbidH. ElbaraziI. ElhabashyH.R. ElhadiM. El-JaafaryS.I. EshratiB. EskandariehS. EsmaeilzadehF. EtemadiA. EzzikouriS. FaisaluddinM. FaraonE.J.A. FaresJ. FarzadfarF. FerozeA.H. FerreroS. Ferro DesideriL. FilipI. FischerF. FisherJ.L. ForoutanM. FukumotoT. GaalP.A. GadM.M. GadanyaM.A. GallusS. Gaspar FonsecaM. Getachew ObsaA. GhafourifardM. GhashghaeeA. GhithN. GholamalizadehM. GilaniS.A. GinindzaT.G. GizawA.T.T. GlasbeyJ.C. GolechhaM. GoleijP. GomezR.S. GopalaniS.V. GoriniG. GoudarziH. GrossoG. GubariM.I.M. GuerraM.R. GuhaA. GunasekeraD.S. GuptaB. GuptaV.B. GuptaV.K. GutiérrezR.A. Hafezi-NejadN. HaiderM.R. Haj-MirzaianA. HalwaniR. HamadehR.R. HameedS. HamidiS. HanifA. HaqueS. HarliantoN.I. HaroJ.M. HasaballahA.I. HassanipourS. HayR.J. HayS.I. HayatK. HeidariG. HeidariM. Herrera-SernaB.Y. HerteliuC. HezamK. HollaR. HossainM.M. HossainM.B.H. HosseiniM.S. HosseiniM. HosseinzadehM. HostiucM. HostiucS. HousehM. HsairiM. HuangJ. HugoF.N. HussainR. HusseinN.R. HwangB.F. IavicoliI. IbitoyeS.E. IdaF. IkutaK.S. IlesanmiO.S. IlicI.M. IlicM.D. IrhamL.M. IslamJ.Y. IslamR.M. IslamS.M.S. IsmailN.E. IsolaG. IwagamiM. JacobL. JainV. JakovljevicM.B. JavaheriT. JayaramS. JazayeriS.B. JhaR.P. JonasJ.B. JooT. JosephN. JoukarF. JürissonM. KabirA. KahriziD. KalankeshL.R. KalhorR. KaliyadanF. KalkondeY. KamathA. Kameran Al-SalihiN. KandelH. KapoorN. KarchA. KasaA.S. KatikireddiS.V. KauppilaJ.H. KavetskyyT. KebedeS.A. KeshavarzP. KeykhaeiM. KhaderY.S. KhalilovR. KhanG. KhanM. KhanM.N. KhanM.A.B. KhangY.H. KhaterA.M. KhayamzadehM. KimG.R. KimY.J. KisaA. KisaS. Kissimova-SkarbekK. KopecJ.A. KoteeswaranR. KoulP.A. Koulmane LaxminarayanaS.L. KoyanagiA. Kucuk BicerB. KugbeyN. KumarG.A. KumarN. KumarN. KurmiO.P. KutlukT. La VecchiaC. LamiF.H. LandiresI. LauriolaP. LeeS. LeeS.W.H. LeeW.C. LeeY.H. LeighJ. LeongE. LiJ. LiM.C. LiuX. LoureiroJ.A. LuneviciusR. Magdy Abd El RazekM. MajeedA. MakkiA. MaleS. MalikA.A. MansourniaM.A. MartiniS. MasoumiS.Z. MathurP. McKeeM. MehrotraR. MendozaW. MenezesR.G. MengeshaE.W. MesregahM.K. MestrovicT. Miao JonassonJ. MiazgowskiB. MiazgowskiT. MichalekI.M. MillerT.R. MirzaeiH. MirzaeiH.R. MisraS. MithraP. MoghadaszadehM. MohammadK.A. MohammadY. MohammadiM. MohammadiS.M. Mohammadian-HafshejaniA. MohammedS. MokaN. MokdadA.H. MolokhiaM. MonastaL. MoniM.A. MoosaviM.A. MoradiY. MoragaP. Morgado-da-CostaJ. MorrisonS.D. MosapourA. MubarikS. MwanriL. NagarajanA.J. NagarajuS.P. NagataC. NaimzadaM.D. NangiaV. NaqviA.A. Narasimha SwamyS. NdejjoR. NduagubaS.O. NegoiI. NegruS.M. Neupane KandelS. NguyenC.T. NguyenH.L.T. NiaziR.K. NnajiC.A. NoorN.M. Nuñez-SamudioV. NzoputamC.I. OanceaB. OchirC. OdukoyaO.O. OgboF.A. OlagunjuA.T. OlakundeB.O. OmarE. Omar BaliA. OmonisiA.E.E. OngS. OnwujekweO.E. OrruH. Ortega-AltamiranoD.V. OtstavnovN. OtstavnovS.S. OwolabiM.O. P AM. PadubidriJ.R. PakshirK. PanaA. PanagiotakosD. Panda-JonasS. PardhanS. ParkE.C. ParkE.K. Pashazadeh KanF. PatelH.K. PatelJ.R. PatiS. PattanshettyS.M. PaudelU. PereiraD.M. PereiraR.B. PerianayagamA. PillayJ.D. PirouzpanahS. PishgarF. PodderI. PostmaM.J. PourjafarH. PrashantA. PreotescuL. RabieeM. RabieeN. RadfarA. RadhakrishnanR.A. RadhakrishnanV. RafieeA. RahimF. RahimzadehS. RahmanM. RahmanM.A. RahmaniA.M. RajaiN. RajeshA. RakovacI. RamP. RamezanzadehK. RanabhatK. RanasingheP. RaoC.R. RaoS.J. RawassizadehR. RazeghiniaM.S. RenzahoA.M.N. RezaeiN. RezaeiN. RezapourA. RobertsT.J. RodriguezJ.A.B. RohloffP. RomoliM. RonfaniL. RoshandelG. RwegereraG.M. SM. SabourS. SaddikB. SaeedU. SahebkarA. SahooH. SalehiS. SalemM.R. SalimzadehH. SamaeiM. SamyA.M. SanabriaJ. SankararamanS. Santric-MilicevicM.M. SardiwallaY. SarveazadA. SathianB. SawhneyM. SaylanM. SchneiderI.J.C. SekerijaM. SeylaniA. ShafaatO. ShaghaghiZ. ShaikhM.A. ShamsoddinE. ShannawazM. SharmaR. SheikhA. SheikhbahaeiS. ShettyA. ShettyJ.K. ShettyP.H. ShibuyaK. ShirkoohiR. ShivakumarK.M. ShivarovV. SiabaniS. Siddappa MalleshappaS.K. SilvaD.A.S. SinghJ.A. SintayehuY. SkryabinV.Y. SkryabinaA.A. SoebergM.J. Sofi-MahmudiA. SotoudehH. SteiropoulosP. StraifK. SubediR. SufiyanM.B. SultanI. SultanaS. SurD. SzerencsésV. SzócskaM. Tabarés-SeisdedosR. TabuchiT. TadbiriH. TaherkhaniA. TakahashiK. TalaatI.M. TanK.K. TatV.Y. TedlaB.A.A. TeferaY.G. Tehrani-BanihashemiA. TemsahM.H. TesfayF.H. TessemaG.A. ThaparR. ThavamaniA. Thoguluva ChandrasekarV. ThomasN. TohidinikH.R. TouvierM. Tovani-PaloneM.R. TrainiE. TranB.X. TranK.B. TranM.T.N. TripathyJ.P. TusaB.S. UllahI. UllahS. UmapathiK.K. UnnikrishnanB. UpadhyayE. VacanteM. VaeziM. Valadan TahbazS. VelazquezD.Z. VerouxM. ViolanteF.S. VlassovV. VoB. VoloviciV. VuG.T. WaheedY. WamaiR.G. WardP. WenY.F. WestermanR. WinklerA.S. YadavL. Yahyazadeh JabbariS.H. YangL. YayaS. YazieT.S.Y. YeshawY. YonemotoN. YounisM.Z. YousefiZ. YuC. YuceD. YunusaI. ZadnikV. ZareF. ZastrozhinM.S. ZastrozhinaA. ZhangJ. ZhongC. ZhouL. ZhuC. ZiapourA. ZimmermannI.R. FitzmauriceC. MurrayC.J.L. ForceL.M. Global burden of disease 2019 cancer collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019.JAMA Oncol.20228342044410.1001/jamaoncol.2021.698734967848
     [Google Scholar]
  4. AzadnajafabadS. MoghaddamS.S. KeykhaeiM. ShobeiriP. RezaeiN. GhasemiE. MohammadiE. AhmadiN. GhamariA. ShahinS. RezaeiN. AghiliM. KavianiA. LarijaniB. FarzadfarF. Expansion of the quality of care index on breast cancer and its risk factors using the global burden of disease study 2019.Cancer Med.20231221729174310.1002/cam4.495135770711
     [Google Scholar]
  5. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  6. HaunerD. HaunerH. Metabolic syndrome and breast cancer: Is there a link?Breast Care20149427728110.1159/00036595125404888
     [Google Scholar]
  7. KaradagM.K. AkbulutM. Low HDL levels as the most common metabolic syndrome risk factor in heart failure.Int. Heart J.200950557158010.1536/ihj.50.57119809206
     [Google Scholar]
  8. DenisenkoYulia K. Lipid-induced mechanisms of metabolic syndrome.J. Obes.20202020576239510.1155/2020/5762395
     [Google Scholar]
  9. De SantiM. AnnibaliniG. MaranoG. BiganzoliG. VenturelliE. PellegriniM. LucertiniF. BrandiG. BiganzoliE. BarbieriE. VillariniA. Association between metabolic syndrome, insulin resistance, and IGF-1 in breast cancer survivors of DIANA-5 study.J. Cancer Res. Clin. Oncol.2023149118639864810.1007/s00432‑023‑04755‑637106164
     [Google Scholar]
  10. NussbaumerovaB. RosolovaH. Obesity and dyslipidemia.Curr. Atheroscler. Rep.2023251294795510.1007/s11883‑023‑01167‑237979064
     [Google Scholar]
  11. JhaB.K. SherpaM.L. ImranM. MohammedY. JhaL.A. PaudelK.R. JhaS.K. Progress in understanding metabolic syndrome and knowledge of its complex pathophysiology.Diabetology20234213415910.3390/diabetology4020015
     [Google Scholar]
  12. AvgerinosK.I. SpyrouN. MantzorosC.S. DalamagaM. Obesity and cancer risk: Emerging biological mechanisms and perspectives.Metabolism20199212113510.1016/j.metabol.2018.11.00130445141
     [Google Scholar]
  13. SeilerA. ChenM.A. BrownR.L. FagundesC.P. Obesity, dietary factors, nutrition, and breast cancer risk.Curr. Breast Cancer Rep.2018101142710.1007/s12609‑018‑0264‑030662586
     [Google Scholar]
  14. YaoX. TianZ. Dyslipidemia and colorectal cancer risk: A meta-analysis of prospective studies.Cancer Causes Control201526225726810.1007/s10552‑014‑0507‑y25488827
     [Google Scholar]
  15. LiC. YangL. ZhangD. JiangW. Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer.Nutr. Res.201636762763510.1016/j.nutres.2016.04.00927333953
     [Google Scholar]
  16. SantosR.C. DominguesG. MatiasI. MatosJ. FonsecaI. de AlmeidaJ.M. DiasS. LDL-cholesterol signaling induces breast cancer proliferation and invasion.Lipids Health Dis.20141311610.1186/1476‑511X‑13‑1624428917
     [Google Scholar]
  17. AntalisC.J. UchidaA. BuhmanK.K. SiddiquiR.A. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification.Clin. Exp. Metastasis201128873374110.1007/s10585‑011‑9405‑921744083
     [Google Scholar]
  18. GuanX. LiuZ. ZhaoZ. ZhangX. TaoS. YuanB. ZhangJ. WangD. LiuQ. DingY. Emerging roles of low-density lipoprotein in the development and treatment of breast cancer.Lipids Health Dis.201918113710.1186/s12944‑019‑1075‑731182104
     [Google Scholar]
  19. LuC.W. LoY.H. ChenC.H. LinC.Y. TsaiC.H. ChenP.J. YangY.F. WangC.H. TanC.H. HouM.F. YuanS.S.F. VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis.Cancer Lett.201738813013810.1016/j.canlet.2016.11.03327940127
     [Google Scholar]
  20. GreifeA. TukovaJ. SteinhoffC. ScottS.D. SchulzW.A. HatinaJ. Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.Tumour Biol.20153653293330010.1007/s13277‑014‑2959‑925566959
     [Google Scholar]
  21. HultschS. KankainenM. PaavolainenL. KovanenR.M. IkonenE. KangaspeskaS. PietiäinenV. KallioniemiO. Association of tamoxifen resistance and lipid reprogramming in breast cancer.BMC Cancer201818185010.1186/s12885‑018‑4757‑z30143015
     [Google Scholar]
  22. WeberP. WagnerM. SchneckenburgerH. Cholesterol dependent uptake and interaction of doxorubicin in mcf-7 breast cancer cells.Int. J. Mol. Sci.20131448358836610.3390/ijms1404835823591847
     [Google Scholar]
  23. GuoL. Breast cancer heterogeneity and its implication in personalized precision therapy.Exp. Hematol. Oncol.2023121310.1186/s40164‑022‑00363‑1
     [Google Scholar]
  24. RakhaE.A. TseG.M. QuinnC.M. An update on the pathological classification of breast cancer.Histopathology202382151610.1111/his.1478636482272
     [Google Scholar]
  25. BursteinH.J. TeminS. AndersonH. BuchholzT.A. DavidsonN.E. GelmonK.E. GiordanoS.H. HudisC.A. RowdenD. SolkyA.J. StearnsV. WinerE.P. GriggsJ.J. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update.J. Clin. Oncol.201432212255226910.1200/JCO.2013.54.225824868023
     [Google Scholar]
  26. KoboldtD.C. FultonR.S. McLellanM.D. SchmidtH. VeizerK.J. McMichaelJ.F. FultonL.L. DoolingD.J. DingL. MardisE.R. Comprehensive molecular portraits of human breast tumours.Nature20124907418617010.1038/nature1141223000897
     [Google Scholar]
  27. YersalO. BarutcaS. Biological subtypes of breast cancer: Prognostic and therapeutic implications.World J. Clin. Oncol.20145341242410.5306/wjco.v5.i3.41225114856
     [Google Scholar]
  28. YoonJ. OhD.Y. HER2-targeted therapies beyond breast cancer - An update.Nat. Rev. Clin. Oncol.202421967570010.1038/s41571‑024‑00924‑939039196
     [Google Scholar]
  29. BaranovaA. Triple-negative breast cancer: Current treatment strategies and factors of negative prognosis.J. Med. Life.202215215316110.25122/jml‑2021‑0108
     [Google Scholar]
  30. HaukaasT.H. EucedaL.R. GiskeødegårdG.F. LamichhaneS. KrohnM. JernströmS. AureM.R. LingjærdeO.C. SchlichtingE. GarredØ. DueE.U. MillsG.B. SahlbergK.K. DaleB.A.L. BathenT.F. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes.Cancer Metab.2016411210.1186/s40170‑016‑0152‑x27350877
     [Google Scholar]
  31. CappellettiV. Metabolic footprints and molecular subtypes in breast cancer.Dis Markers.201720177687851
     [Google Scholar]
  32. KimS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes.PloS one20152015e0119473
     [Google Scholar]
  33. MonacoM.E. Fatty acid metabolism in breast cancer subtypes.Oncotarget.2017817294872950010.18632/oncotarget.15494
     [Google Scholar]
  34. LuoJ. YangH. SongB.L. Mechanisms and regulation of cholesterol homeostasis.Nat. Rev. Mol. Cell Biol.202021422524510.1038/s41580‑019‑0190‑731848472
     [Google Scholar]
  35. WangY. YutucE. GriffithsW.J. Cholesterol metabolism pathways – Are the intermediates more important than the products?FEBS J.2021288123727374510.1111/febs.1572733506652
     [Google Scholar]
  36. GoldsteinJ.L. BrownM.S. The ldl receptor and the regulation of cellular cholesterol metabolism.J. Cell Sci.19851985Suppl. 313113710.1242/jcs.1985.Supplement_3.133914990
     [Google Scholar]
  37. MaitiB. KundrandaM.N. SpiroT.P. DawH.A. The association of metabolic syndrome with triple-negative breast cancer.Breast Cancer Res. Treat.2010121247948310.1007/s10549‑009‑0591‑y19851862
     [Google Scholar]
  38. DuSellC.D. UmetaniM. ShaulP.W. MangelsdorfD.J. McDonnellD.P. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.Mol. Endocrinol.2008221657710.1210/me.2007‑038317872378
     [Google Scholar]
  39. SimigdalaN. GaoQ. PancholiS. LarsenR.H. ZvelebilM. RibasR. FolkerdE. ThompsonA. BhamraA. DowsettM. MartinL.A. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.Breast Cancer Res.20161815810.1186/s13058‑016‑0713‑527246191
     [Google Scholar]
  40. GyőrffyB. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.Comput. Struct. Biotechnol. J.2021194101410910.1016/j.csbj.2021.07.01434527184
     [Google Scholar]
  41. TomczakK. CzerwińskaP. WiznerowiczM. Review the cancer genome atlas (TCGA): An immeasurable source of knowledge.Contemp Oncol2015191AA687710.5114/wo.2014.47136
     [Google Scholar]
  42. LánczkyA. GyőrffyB. Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation.J. Med. Internet Res.2021237e2763310.2196/2763334309564
     [Google Scholar]
  43. BenjaminiY. HochbergY. Controlling the false discovery rate: A practical and powerful approach to multiple testing.J. R. Stat. Soc. Series B Stat. Methodol.199557128930010.1111/j.2517‑6161.1995.tb02031.x
     [Google Scholar]
  44. LoveM.I. HuberW. AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol.2014151255010.1186/s13059‑014‑0550‑825516281
     [Google Scholar]
  45. KimH.Y. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test.Restor. Dent. Endod201742215215510.5395/rde.2017.42.2.15228503482
     [Google Scholar]
  46. SeaboldS. PerktoldJ. Statsmodels: Econometric and statistical modeling with python.SciPy20107929610.25080/Majora‑92bf1922‑011
     [Google Scholar]
  47. AbdiH. WilliamsL.J. Tukey’s honestly significant difference (HSD) test.Encycl. Res. Des.201015661570
     [Google Scholar]
  48. WuS.Z. Al-EryaniG. RodenD.L. JunankarS. HarveyK. AnderssonA. ThennavanA. WangC. TorpyJ.R. BartonicekN. WangT. LarssonL. KaczorowskiD. WeisenfeldN.I. UytingcoC.R. ChewJ.G. BentZ.W. ChanC.L. GnanasambandapillaiV. DutertreC.A. GluchL. HuiM.N. BeithJ. ParkerA. RobbinsE. SegaraD. CooperC. MakC. ChanB. WarrierS. GinhouxF. MillarE. PowellJ.E. WilliamsS.R. LiuX.S. O’TooleS. LimE. LundebergJ. PerouC.M. SwarbrickA. A single-cell and spatially resolved atlas of human breast cancers.Nat. Genet.20215391334134710.1038/s41588‑021‑00911‑134493872
     [Google Scholar]
  49. HaoY. StuartT. KowalskiM.H. ChoudharyS. HoffmanP. HartmanA. SrivastavaA. MollaG. MadadS. GrandaF.C. SatijaR. Dictionary learning for integrative, multimodal and scalable single-cell analysis.Nat. Biotechnol.202342229330410.1038/s41587‑023‑01767‑y37231261
     [Google Scholar]
  50. WalshC.A. The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.PLoS One2020157e023618710.1371/journal.pone.0236187
     [Google Scholar]
  51. GöbelA. Cholesterol and beyond-The role of the mevalonate pathway in cancer biology.Biochim. Biophys. Acta. Rev. Cancer202018732188351
     [Google Scholar]
  52. BlochK. The biological synthesis of cholesterol.Science19651503692192810.1126/science.150.3692.195319508
     [Google Scholar]
  53. MitscheM.A. McDonaldJ.G. HobbsH.H. CohenJ.C. Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways.eLife20154e0799910.7554/eLife.0799926114596
     [Google Scholar]
  54. XianM. WangQ. XiaoL. ZhongL. XiongW. YeL. SuP. ZhangC. LiY. OrlowskiR.Z. ZhanF. GangulyS. ZuY. QianJ. YiQ. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis.Nat. Commun.2024151576710.1038/s41467‑024‑50073‑x38982045
     [Google Scholar]
  55. WuY.X. WangY. Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor.Yi Chuan20204210965978
     [Google Scholar]
  56. SharpeL.J. BrownA.J. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).J. Biol. Chem.201328826187071871510.1074/jbc.R113.47980823696639
     [Google Scholar]
  57. BorgquistS. DjerbiS. PonténF. AnagnostakiL. GoldmanM. GaberA. ManjerJ. LandbergG. JirströmK. HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.Int. J. Cancer200812351146115310.1002/ijc.2359718528862
     [Google Scholar]
  58. LüöndF. TiedeS. ChristoforiG. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.Br. J. Cancer2021125216417510.1038/s41416‑021‑01328‑733824479
     [Google Scholar]
  59. YeF. Cancer-associated fibroblasts facilitate breast cancer progression through exosomal circTBPL1-mediated intercellular communication.Cell Death Dis202314747110.1038/s41419‑023‑05986‑8
     [Google Scholar]
  60. GaoY. CD63+ cancer-associated fibroblasts confer tamoxifen resistance to breast cancer cells through exosomal miR-22.Adv. Sci.2020721200251810.1002/advs.202002518
     [Google Scholar]
  61. RivasE.I. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.Nat. Commun.2022131531010.1038/s41467‑022‑32782‑3
     [Google Scholar]
  62. SantosZ.D. de SouzaJ.C. PimentaT.M. MartinsS.B. JuniorR.S.R. ButzeneS.M.S. TessaroloN.G. CilasP.M.L.Jr SilvaI.V. RangelL.B.A. The impact of lipid metabolism on breast cancer: A review about its role in tumorigenesis and immune escape.Cell Commun. Signal.202321116110.1186/s12964‑023‑01178‑137370164
     [Google Scholar]
  63. EhmsenS. PedersenM.H. WangG. TerpM.G. ArslanagicA. HoodB.L. ConradsT.P. LarsenL.R. DitzelH.J. Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome.Cell Rep.2019271339273938.e610.1016/j.celrep.2019.05.10431242424
     [Google Scholar]
  64. O’GradyS. CrownJ. DuffyM.J. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.Med. Oncol.2022391014210.1007/s12032‑022‑01733‑9
     [Google Scholar]
  65. SantosZ.D. GuimaraesS.I. SanniH.M.F. CochranB.J. RyeK.A. GrewalT. HoyA.J. RangelL.B.A. Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells.Discov. Oncol.202213113510.1007/s12672‑022‑00598‑836481936
     [Google Scholar]
  66. SimY. LimC. PhyuN. TanK.T.B. ChewL.S.T. WongC.Y. MadhukumarP. YongW.S. LimS.Z. HamzahJ.L.B. TanS.Y. ChayW.Y. WongF.Y. TanP.H. TanV.K.M. The impact of statin use and breast cancer recurrence-A retrospective study in Singapore.Front. Oncol.20221283532010.3389/fonc.2022.83532035433431
     [Google Scholar]
  67. SinhaK.C. IgnatoskiK.W. LippmanM.E. EthierS.P. ChinnaiyanA.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.Cancer Res.200363113213912517789
     [Google Scholar]
  68. CalvoG.D. VilaróL.L. NasarreL. OlabarriaP.M. VázquezT. EscuinD. BadimonL. BarnadasA. LermaE. CortésL.V. Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: A molecular and clinicopathological study.BMC Cancer201515146010.1186/s12885‑015‑1469‑526055977
     [Google Scholar]
  69. MartinH.G. RivasL.A. Statins activate a mitochondria- operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins.FEBS Lett.2008582172589259410.1016/j.febslet.2008.06.03418582466
     [Google Scholar]
  70. ZhangJ. LiQ. WuY. WangD. XuL. ZhangY. WangS. WangT. LiuF. ZakyM.Y. HouS. LiuS. ZouK. LeiH. ZouL. ZhangY. LiuH. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.Cell Commun. Signal.20191711510.1186/s12964‑019‑0328‑430786890
     [Google Scholar]
  71. LiX. TangH. WangJ. XieX. LiuP. KongY. YeF. ShuangZ. XieZ. XieX. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer.Breast2017321610.1016/j.breast.2016.11.02427939967
     [Google Scholar]
  72. SantosR.C. FonsecaI. DiasS. AlmeidaM.J.C. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression.BMC Cancer201414113210.1186/1471‑2407‑14‑13224571647
     [Google Scholar]
  73. WyheV.R. RahalO. WoodwardW. Effect of statins on breast cancer recurrence and mortality: A review.Breast Cancer2017955956510.2147/BCTT.S14808029238220
     [Google Scholar]
  74. AntalisC.J. ArnoldT. RasoolT. LeeB. BuhmanK.K. SiddiquiR.A. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation.Breast Cancer Res. Treat.2010122366167010.1007/s10549‑009‑0594‑819851860
     [Google Scholar]
  75. YuanQ. LuX. GuoH. SunJ. YangM. LiuQ. TongM. Low-density lipoprotein receptor promotes crosstalk between cell stemness and tumor immune microenvironment in breast cancer: A large data-based multi-omics study.J. Transl. Med.202321187110.1186/s12967‑023‑04699‑y38037058
     [Google Scholar]
  76. HsuC.Y. AbdulrahimM.N. MustafaM.A. OmarT.M. BaltoF. PinedaI. KhudairT.T. UbaidM. AliM.S. The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy.Med. Oncol.202441820210.1007/s12032‑024‑02435‑039008137
     [Google Scholar]
  77. ChongW.E. JoncasF.H. SeidahN.G. CalonF. DiorioC. GangloffA. Circulating levels of PCSK9, ANGPTL3 and Lp(A) in stage III breast cancers.BMC Cancer2022221104910.1186/s12885‑022‑10120‑636203122
     [Google Scholar]
  78. LlaveriasG. DaniloC. MercierI. DaumerK. CapozzaF. WilliamsT.M. SotgiaF. LisantiM.P. FrankP.G. Role of cholesterol in the development and progression of breast cancer.Am. J. Pathol.2011178140241210.1016/j.ajpath.2010.11.00521224077
     [Google Scholar]
  79. NowakC. ÄrnlövJ. A Mendelian randomization study of the effects of blood lipids on breast cancer risk.Nat. Commun.201891395710.1038/s41467‑018‑06467‑9
     [Google Scholar]
  80. BorojeniM.A.A. NikE.M. JaafariR.M. BanachM. SahebkarA. Effects of immunization against PCSK9 in an experimental model of breast cancer.Arch. Med. Sci.201915357057910.5114/aoms.2019.8473431110521
     [Google Scholar]
  81. SunY. ZhangH. MengJ. GuoF. RenD. WuH. JinX. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.Cell Rep.202240711119410.1016/j.celrep.2022.11119435977495
     [Google Scholar]
  82. YangK. ZhuJ. LuoH. YuS. WangL. Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in Apc Min/+ mice.Int. J. Immunopathol. Pharmacol.2021352058738421103834510.1177/2058738421103834534586888
     [Google Scholar]
  83. JinW. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial–mesenchymal transition.Cells20209121710.3390/cells9010217
     [Google Scholar]
  84. BernardiS. MarcuzziA. PiscianzE. TommasiniA. FabrisB. The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases.Int. J. Mol. Sci.20181912405810.3390/ijms1912405830558209
     [Google Scholar]
  85. LiuX. BaoX. HuM. ChangH. JiaoM. ChengJ. XieL. HuangQ. LiF. LiC.Y. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.Nature2020588783969369810.1038/s41586‑020‑2911‑733177715
     [Google Scholar]
  86. YuanJ. CaiT. ZhengX. RenY. QiJ. LuX. ChenH. LinH. ChenZ. LiuM. HeS. ChenQ. FengS. WuY. ZhangZ. DingY. YangW. Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling.Protein Cell202112424026010.1007/s13238‑021‑00821‑233606190
     [Google Scholar]
  87. LeiK. KurumA. KaynakM. BonatiL. HanY. CencenV. GaoM. XieY.Q. GuoY. HannebelleM.T.M. WuY. ZhouG. GuoM. FantnerG.E. SakarM.S. TangL. Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy.Nat. Biomed. Eng.20215121411142510.1038/s41551‑021‑00826‑634873307
     [Google Scholar]
  88. WangR. LiuH. HeP. AnD. GuoX. ZhangX. FengM. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells.Front. Immunol.20221394775610.3389/fimmu.2022.94775636003387
     [Google Scholar]
  89. WangLu. PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages.J. Exp. Clin. Cancer Res202241130310.1186/s13046‑022‑02477‑0
     [Google Scholar]
  90. LebeauP.F. PlatkoK. ByunJ.H. MakdaY. AustinR.C. The emerging roles of intracellular PCSK9 and their implications in endoplasmic reticulum stress and metabolic diseases.Metabolites202212321510.3390/metabo1203021535323658
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673291217241219055416
Loading
The Expression of the LDLR, LDLRAP1, and PCSK9 Genes has Prognostic Significance in Triple-negative Breast Cancer
Curr. Med. Chem. 32, 7045 (2025); https://doi.org/10.2174/0109298673291217241219055416
/content/journals/cmc/10.2174/0109298673291217241219055416
/content/journals/cmc/10.2174/0109298673291217241219055416
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): basal-like; Breast cancer; cholesterol; HER2+; LDLR; PCSK9; triple-negative

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test